11.I In-process control Authors: Dr. Christian Gausepohl / Paolomi Mukherji / Update 07

Size: px
Start display at page:

Download "11.I In-process control Authors: Dr. Christian Gausepohl / Paolomi Mukherji / Update 07"

Transcription

1 In-process control In-process control Authors: Dr. Christian Gausepohl / Paolomi Mukherji / Update 07 Here you will find answers to the following questions: What are the in-process control tasks? Where should the in-process control group be established in organisational and disciplinary terms? How are the responsibilities regulated? How are in-process controls carried out? In-process controls (IPC) are checks that are carried out before the manufacturing process is completed. The function of in-process controls is monitoring and if necessary adaptation of the manufacturing process in order to comply with the specifications. This may include control of equipment and environment, too. In-process materials should be tested for identity, strength, quality and purity as appropriate and approved or rejected by the Quality Control unit during the production process. Rejected in-process materials should be identified and controlled under a quarantine system designed to prevent their use in manufacturing. Written procedures should be established and followed that describe the In-process controls and tests as specified: Tablet or capsule weight variation, Disintegration time, Content uniformity and homogeneity, Dissolution time and rate, Clarity, completeness or ph of solutions. In-process controls may be performed in regular intervals during a process step (e.g. tabletting, encapsulation) or at the end of a process step (e.g. granulation, blending). The objectives of in-process control are both quality control and process control. (1)

2 11 Production.1 Objectives.1.1 Quality control This function is performed by documenting production parameters. In a broader sense, this includes the following in-process controls: measured values obtained from process equipment, e.g. temperatures measured values obtained by persons, e.g. times product attributes, e.g. weight, hardness, friability measured values obtained from the room environment, e.g. particle counts tests following completion of intermediate products The classic interpretation of the term in-process control includes the recording of measured values by members of the in-process control group. Finished product assessment should embrace all relevant factors, including [ ] results of in-process testing, [ ] (6.3 EU-GMP-Guide, see chapter C.4). The documented in-process data are therefore evaluated by quality control. In accordance with 21 CFR , in-process results are evaluated by quality control in the context of batch record review (see chapter D CFR 211 Current Good Manufacturing Practice for Finished Pharmaceuticals). This evaluation is part of the release procedure (see chapter 14.J Batch release). The investigation of intermediate manufacturing steps also falls into the category of in-process controls. An example of this is the homogeneity investigation carried out on a blend. Normally, such quantitative determinations are the direct responsibility of quality control. In a broader sense, yields of the various intermediate products are also in-process control values..1.2 Process control (2) During manufacturing and packaging a lot of data are recorded which represent control factors of the manufacturing process. These data may be process parameters (e.g. outlet air temperature of a fluid bed dryer) or product attributes (e.g. hardness of tablet cores). The results of the measurements may indicate that a corrective action is required to maintain the process and the product within the specified ranges. The limits within which modifications may be carried out to match measured values must be determined in advance. The drying of a granulate is described here as an example. The objective, i.e. the resultant granulate humidity, is determined within the scope of the manufacturing instructions. If the specified range has not yet been achieved, the normal course of action is to extend the drying time. In this case, it is irrelevant whether the control is automatic, e.g. by means of online measurement within a fluid bed dryer or manual sampling. The principle of this control function is shown in figure -1.

3 In-process control Processing step A IPC Unit of measurement Specification fulfilled? YES NO Processing step B Figure -1 Process control by means of in-process controls.2 Organisation and responsibilities Precise information about the area of responsibility to which the accomplishment of in-process controls is to be assigned cannot be found in the EU-GMP-Guide. There is merely the requirement that the procedures have to be authorized by quality control. All the in-process controls, including those made in the production area by production personnel, should be performed according to methods approved by Quality Control and the results recorded. (6.18 EU-GMP-Guide, see chapter C.4). Usually, the tests are carried out by production personnel. This is favourable for organizational and timely reasons, e.g. in a multi-shift operation. The personnel in the production area referred to here do not have to be directly responsible to the head of production with disciplinary responsibility. On the basis of organisational instructions and process descriptions, quality control personnel may also carry out the necessary tasks. The head of production is responsible for carrying out the controls in every case. He or she must ensure that the controls are used as a means of controlling processes in accordance with the instructions, and that the results are taken into account. (3)

4 11 Production In the case of quality assurance checks, it is recommended from a disciplinary point of view that in-process control personnel are organised independently of production personnel, i.e. that they report directly to their area manager. This group therefore gains more autonomy in relation to production personnel. This is necessary as the group must occasionally make decisions to stop or cancel manufacturing steps (see figure -2). 21 CFR (c) states that the responsibility for quality assuring tests lies within the quality control unit (see chapter D.1.2). Head Production group IPC group Control function Check function Process Figure -2 Example of an organisational structure The responsibilities and tasks for the in-process control must be clearly laid down in organisational instructions. A number of aspects has to be considered (figure -3) When deviations occur, or where release analyses of intermediates are carried out outside of production, a method must be defined that prevents continued processing of the material until the decision or the result is available. Material may be rejected by means of operating data management whereby the process chain is interrupted. Physical designation of the product affected by means of labelling is recommended..3 Carrying out.3.1 Scope and kind of tests (4) The in-process control requirements are documented in the manufacturing instructions. For logical reasons, these requirements are compiled together by

5 In-process control Responsibilities in the context of in-process controls Task Definition of tests Compilation and approval of the test procedure Taking samples (mechanical/manual) Transportation of the samples to the test laboratory Performing tests Responsibility Head of manufacturing Head of quality control and Head of manufacturing IPC personnel, production personnel, monitors Process control information paths Approval of equipment Head of manufacturing Measures in the event of deviations Evaluation of IPC results Quality Control Quality Assurance / Quality Unit Figure -3 Responsibilities development, manufacturing and quality control. The parameters and experiences accumulated during the process validation determine the scope of the tests as well as the limits. The scope of the tests depends on the extent of process control, i.e. the more reliable the process, the smaller the scope of the tests. The types of tests carried out depend on the dosage forms being produced. Physical and attributive features are mainly checked (see figure -4). Physical parameters are checked using only suitable measuring instruments. These instruments are normally calibrated by in-process control personnel. It may also be advantageous to have measuring instruments in production areas (e.g. balances) calibrated by in-process control personnel. Operating procedures (SOPs) are used as the basis for the tests together with the manufacturing instructions. The approval of these instructions by quality control ensures that the test complies with the requirements (normally according to the pharmacopoeia). The testing of attributive criteria is an important in-process control task. This is particularly of importance in relation to the filling of solutions and solid dosage forms as well as packaging. AQL lists (AQL = Acceptance Quality Limit) are normally used as the basis for the test procedures/specifications. (See chapter 13.A.5 Packaging material testing.) With many manufacturing operations, release tests are an important in-process control task for starting up equipment or processes. These are special control loop applications (see figure -5). (5)

6 11 Production Examples of in-process controls Physical parameters temperature time pressure weight hardness disintegration time particle size loss on drying viscosity osmolarity ph Attributive features visible impurity colour completeness integrity fractional part Figure -4 Examples of in-process controls Preparation of tablet press IPC Start-up sample Specification fulfilled? YES NO Start of production Figure -5 Example of approval for tablet production (6)

7 In-process control.3.2 Location In-process controls may be carried out within the production area provided they do not carry any risk for the production. (3.17 EU-GMP-Guide, see chapter C.4). This means that particular care must be taken when carrying out sampling or testing. Examples of possible influences of in-process control methods on production are shown below: Particle measurements (influence on air flow pattern) Direct contact tests (matrix residues on surface) Disintegration tests (influence on room humidity) Leak test on blisters (blue bath with microbial contamination risk) Tests are therefore normally carried out in a segregated area and not directly at the manufacturing location. To keep equipment expenditure to a minimum, central in-process control laboratories are occasionally set up to carry out tests relevant to all areas. In these cases, it must be clarified who is responsible for sampling. Depending on the organisational structure, personnel involved in production, in-process controls or other areas such as quality assurance (sometimes referred to as monitors) may carry out the sampling. Furthermore, analytical equipment and instruments are protected from dust by segregating them physically from the manufacturing location..3.3 Sampling Samples can be differentiated according to their representativeness. Non-representative random samples that intentionally provide a snap-shot of the manufacturing process are used for the purposes of process control. Samples that are generated for the final control are designed as representative samples. Following this principle, uniform sampling is carried out throughout the entire production (batch). As a first step, a sampling plan has to be established, which identifies process steps and/or locations for sampling, as well as number and amount of samples. When defining the amount to be sampled, statistical criteria should be considered and justified, e.g. Component variability Confidence levels Degree of precision Quantity needed for analysis Reserve amount needed (7)

8 11 Production The sampling plan should also contain precise instructions on the sampling procedure, as listed in figure -6. Contents of a sampling procedure State type of sample container to be used Describe collection technique: Prevent contamination of product being sampled, Prevent contamination of sample taken, Aseptic technique if required Specify sampling utensils: Define type and requirements (clean, sterile, pyrogen free) Justify any use of composite sample Describe method for obtaining representative samples Describe scheme for identifying samples: Name of item Lot number Date taken Sampler s name Other Figure -6 Contents of a Sampling Procedure.3.4 Testing Samples are tested to verify conformance with specifications: Identity Component conformity to written specifications Container/Closure conformity to written specifications Examination for contamination As a result, components, containers or closures will be approved or rejected. The tests to be performed and the methods to be used have to be defined. A list of specifications has to be established. Beyond this, procedures for the use of Certificates of Analysis (COA) or Certificate of Conformance have to be established..4 Documentation and evaluation of data (8) When documenting the results of the analysis, care must be taken to ensure that the samples investigated can be assigned to a specific time during the process or to a specific phase of the process. If the analysis is not carried out directly after

9 In-process control sampling, e.g. in the case of central IPC laboratories, the sampling time (date, time) must be documented in addition to the analysis time. Any necessary in-process controls and environmental controls should be carried out and recorded. (5.38 EU-GMP-Guide, chapter C.4). This documentation must include a record of the in-process controls, the initials of the person(s) carrying them out, and the results obtained. If problems or deviations from the manufacturing formula and processing instructions occurred, all relevant information associated with this have to be documented as well. In case of deviations, the signature of the person who approved the deviation is required (4.17 EU-GMP-Guide, chapter C.4). It is hereby clearly stated that each deviation from the specifications must be countersigned by Qualified Persons (see chapter 15.B GMP-conforming documentation). The head of production is responsible for the deviation procedure. Figure -7 shows the information required for documentation of in-process controls. Documentation of in-process controls Date (poss. time), Name of person carrying out the test Results Description of problems In case of deviations: Reasons for deviations Measures incl. justification date and name of authorising person Figure -7 Documentation In-process controls In addition to the numerical compilation of data, a graphical presentation of process control values is recommended. This provides a more simplified overview that makes it possible for trends to be easily detected at an early stage. The manufacturing of tablets is used for the purposes of the following example (see figure - 8). The average weight of 10 tablets is regularly checked in addition to the control of mass uniformity. The values are entered in the graphic data sheet. The control and tolerance limits are added. The measured values should ideally be within the control limits. The machine settings must be adjusted where measurement results fall into the range between the control and tolerance value. Production must be stopped where results are outside the tolerance limits and the cause of this must be found. Reasons must be given for results outside the tolerances. These tests may be carried out mechanically or manually. (9)

10 11 Production Logo GMP Pharma Mat. Des.: Antistress N Mat. no.: Batch des.: 17865A 198 Tolerance level Specified limit Totals weight (n=10) Target 186 Specified limit Tolerance level Sample number Date/ signature / ga Figure -8 In-process control as means of controlling production Summary In-process control not only provides a means of controlling production, it also performs a quality assurance function. The in-process control group personnel may be assigned to production or quality control depending on the relevant company structure. In each case, autonomy in relation to the production process must be ensured. The in-process control methods that are part of the manufacturing formula are compiled and validated under the supervision of quality control. Statistical evaluation and periodic review of in-process data contributes to the general assessment of process performance and product quality. (10)

SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT

SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT SPECIFICATIONS AND CONTROL TESTS ON THE FINISHED PRODUCT Guideline Title Specifications and Control Tests on the Finished Product Legislative basis Directive 75/318/EEC as amended Date of first adoption

More information

[See Rules 74,74-A, 74-B, 78 and 78-A] A. SUBSTANCES OTHER THAN PARENTERAL IN PREPARATIONS IN GENERAL

[See Rules 74,74-A, 74-B, 78 and 78-A] A. SUBSTANCES OTHER THAN PARENTERAL IN PREPARATIONS IN GENERAL 29 [SCHEDULE U [See Rules 74,74-A, 74-B, 78 and 78-A] I. Particulars to the shown in /manufacturing Records A. SUBSTANCES OTHER THAN PARENTERAL IN PREPARATIONS IN GENERAL 1. Serial number. 2. Name of the

More information

Working Party on Control of Medicines and Inspections. Final Version of Annex 15 to the EU Guide to Good Manufacturing Practice

Working Party on Control of Medicines and Inspections. Final Version of Annex 15 to the EU Guide to Good Manufacturing Practice EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals and cosmetics Brussels, July 2001 Working Party on Control

More information

Pharmaceutical Wholesaler Site Inspection Checklist

Pharmaceutical Wholesaler Site Inspection Checklist Pharmaceutical Wholesaler Site Inspection Checklist Date and time of inspection: Legal business name and plant name: Location (address): Phone number: Fax number: Email address: Web site URL: Contact Person:

More information

VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1)

VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY Q2(R1) INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND METHODOLOGY

More information

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products- authorisations, European Medicines Agency Brussels, EudraLex The Rules Governing Medicinal

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Q2B Validation of Analytical Procedures: Methodology November 1996 ICH Guidance for Industry Q2B Validation of Analytical Procedures: Methodology Additional copies are available from:

More information

ALACC Frequently Asked Questions (FAQs)

ALACC Frequently Asked Questions (FAQs) Updated October 17, 2012 ALACC Contents Web Introduction to FAQ... 2 FAQ #6... 3 ALACC Section: How to Meet ISO 17025 Requirements for Method Verification (Page 9)... 3 FAQ #13... 4 ALACC Section ALACC

More information

Guide to Inspections of Tablet Manufacturing Facilities including Pre/Post Approval Issues as per USFDA

Guide to Inspections of Tablet Manufacturing Facilities including Pre/Post Approval Issues as per USFDA International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.4, No.1, pp 49-55, Jan-Mar 2012 Guide to Inspections of Tablet Manufacturing Facilities including Pre/Post Approval

More information

Validation and Calibration. Definitions and Terminology

Validation and Calibration. Definitions and Terminology Validation and Calibration Definitions and Terminology ACCEPTANCE CRITERIA: The specifications and acceptance/rejection criteria, such as acceptable quality level and unacceptable quality level, with an

More information

GENERAL GUIDANCE FOR INSPECTORS ON HOLD-TIME STUDIES

GENERAL GUIDANCE FOR INSPECTORS ON HOLD-TIME STUDIES February 2013 RESTRICTED GENERAL GUIDANCE FOR INSPECTORS ON HOLD-TIME STUDIES DRAFT FOR COMMENT Should you have any comments on the attached text, please send these to Dr Sabine Kopp, Manager, Medicines

More information

ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology. Step 5

ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology. Step 5 European Medicines Agency June 1995 CPMP/ICH/381/95 ICH Topic Q 2 (R1) Validation of Analytical Procedures: Text and Methodology Step 5 NOTE FOR GUIDANCE ON VALIDATION OF ANALYTICAL PROCEDURES: TEXT AND

More information

GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS ANNEX 15 *

GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS ANNEX 15 * PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PS/INF 11/2015 1 April 2015 GUIDE TO GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS ANNEX 15 * * Entry into force:

More information

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public Health and Risk Assessment Pharmaceuticals Brussels, SANCO/C8/AM/sl/ares(2010)1064587 EudraLex The Rules Governing Medicinal Products

More information

Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry

Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry Step-by-Step Analytical Methods Validation and Protocol in the Quality System Compliance Industry BY GHULAM A. SHABIR Introduction Methods Validation: Establishing documented evidence that provides a high

More information

ICH Topic Q 1 A Stability Testing Guidelines: Stability Testing of New Drug Substances and Products

ICH Topic Q 1 A Stability Testing Guidelines: Stability Testing of New Drug Substances and Products The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit CPMP/ICH/380/95 ICH Topic Q 1 A Stability Testing Guidelines: Stability Testing of New Drug Substances and Products

More information

GUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs.

GUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs. 15 January 2007 GUIDELINE ON ACTIVE PHARMACEUTICAL INGREDIENT MASTER FILE (APIMF) PROCEDURE 1 (The APIMF procedure guideline does not apply to biological APIs.) TABLE OF CONTENTS 1 INTRODUCTION... 2 2

More information

MeriCal Quality Profile

MeriCal Quality Profile January 5, 2015 Dear Valued Customer, Since the implementation of new federal regulations, MeriCal Inc. has received a large volume of questionnaires and surveys regarding our services and procedures.

More information

Particle Monitoring Requirements in Pharmaceutical Cleanrooms

Particle Monitoring Requirements in Pharmaceutical Cleanrooms Particle Monitoring Requirements in Pharmaceutical Cleanrooms All drugs must be manufactured in accordance with the current Good Manufacturing Practice (cgmp) regulations. Pharmaceutical manufacturers

More information

Annex 9 Guide to good storage practices for pharmaceuticals 1

Annex 9 Guide to good storage practices for pharmaceuticals 1 World Health Organization WHO Technical Report Series, No. 908, 2003 Annex 9 Guide to good storage practices for pharmaceuticals 1 1. Introduction 125 2. Glossary 126 3. Personnel 128 4. Premises and facilities

More information

Guideline on dossier requirements for Type IA and IB notifications

Guideline on dossier requirements for Type IA and IB notifications Guideline on dossier requirements for Type IA and IB notifications In accordance with Regulation (EC) No 726/2004 and Directives 2001/83/EC and 2001/82/EC, a common approach to the procedures for variations

More information

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union.

EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union. EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 03 February 2010 ENTR/F/2/AM/an D(2010) 3374 EudraLex The Rules Governing Medicinal Products in

More information

OMCL Network of the Council of Europe QUALITY MANAGEMENT DOCUMENT

OMCL Network of the Council of Europe QUALITY MANAGEMENT DOCUMENT OMCL Network of the Council of Europe QUALITY MANAGEMENT DOCUMENT PA/PH/OMCL (11) 204 3R HANDLING AND USE OF REFERENCE STANDARDS IN THE OMCL NETWORK Full document title and reference Document type Legislative

More information

Recent Updates on European Requirements and what QPs are expected to do

Recent Updates on European Requirements and what QPs are expected to do Recent Updates on European Requirements and what QPs are expected to do QP Forum 28/29 November 2013, Lisbon Dr. Bernd Renger Modified: Georg Goestl 1 Written Conformation for API-Import Actual Status

More information

GMP ANNEX 1 REVISION 2008, INTERPRETATION OF MOST IMPORTANT CHANGES FOR THE MANUFACTURE OF STERILE MEDICINAL PRODUCTS

GMP ANNEX 1 REVISION 2008, INTERPRETATION OF MOST IMPORTANT CHANGES FOR THE MANUFACTURE OF STERILE MEDICINAL PRODUCTS PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 032-2 8 January 2010 RECOMMENDATION GMP ANNEX 1 REVISION 2008, INTERPRETATION OF MOST IMPORTANT CHANGES FOR THE MANUFACTURE

More information

Annex 7 Application of Hazard Analysis and Critical Control Point (HACCP) methodology to pharmaceuticals

Annex 7 Application of Hazard Analysis and Critical Control Point (HACCP) methodology to pharmaceuticals World Health Organization WHO Technical Report Series, No. 908, 2003 Annex 7 Application of Hazard Analysis and Critical Control Point (HACCP) methodology to pharmaceuticals 1. Introduction Traditionally,

More information

Corden Pharma Latina S.p.A. 5/20/16

Corden Pharma Latina S.p.A. 5/20/16 Corden Pharma Latina S.p.A. 5/20/16 Department of Health and Human Services Public Health Service Food and Drug Administration Silver Spring, MD 20993 Via UPS Warning Letter 320-16-14 Return Receipt Requested

More information

Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations

Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations Kevin O Donnell PhD Market Compliance Manager, IMB PDA / FDA Conference Pharmaceutical

More information

Workshop B Control Strategy

Workshop B Control Strategy ICH-GCG ASEAN Workshop B Control Strategy Jean-Louis ROBERT, Ph.D. National Health Laboratory, Luxembourg Chair-person ICH IWG Q8, Q9, Q10 Kuala Lumpur, 26-28 July 2010 International Conference on Harmonisation

More information

JANUARY 2013 PREPARATION OF A SITE MASTER FILE FOR A MANUFACTURER OF COSMETIC PRODUCTS

JANUARY 2013 PREPARATION OF A SITE MASTER FILE FOR A MANUFACTURER OF COSMETIC PRODUCTS JANUARY 2013 PREPARATION OF A SITE MASTER FILE FOR A MANUFACTURER OF COSMETIC PRODUCTS 1 WHAT IS A SITE MASTER FILE? A Site Master File (SMF) is a document prepared by the manufacturer containing specific

More information

Annex 2. WHO good manufacturing practices for pharmaceutical products: main principles 1

Annex 2. WHO good manufacturing practices for pharmaceutical products: main principles 1 Annex 2 WHO good manufacturing practices for pharmaceutical products: main principles 1 Introduction 79 General considerations 80 Glossary 81 Quality management in the medicines industry: philosophy and

More information

NSF Dietary Supplement

NSF Dietary Supplement NSF Dietary Supplement SOP Template Book A guide to achieving and maintaining compliance to 21 CFR 111: Dietary Supplement Good Manufacturing Practices 2 Contents How to Use...4 About NSF Dietary Supplements...5

More information

[SCHEDULE M] [See Rules 71, 74, 76 and 78] GOOD MANUFACTURING PRACTICES AND REQUIREMENTS OF PREMISES, PLANT AND EQUIPMENT FOR PHARMACEUTICAL PRODUCTS.

[SCHEDULE M] [See Rules 71, 74, 76 and 78] GOOD MANUFACTURING PRACTICES AND REQUIREMENTS OF PREMISES, PLANT AND EQUIPMENT FOR PHARMACEUTICAL PRODUCTS. [SCHEDULE M] [See Rules 71, 74, 76 and 78] GOOD MANUFACTURING PRACTICES AND REQUIREMENTS OF PREMISES, PLANT AND EQUIPMENT FOR PHARMACEUTICAL PRODUCTS. Note: - To achieve the objectives listed below, each

More information

Good Manufacturing Practices for the Production of Packaging Inks formulated for use on the non food contact surfaces of food packaging and articles

Good Manufacturing Practices for the Production of Packaging Inks formulated for use on the non food contact surfaces of food packaging and articles Good Manufacturing Practices for the Production of Packaging Inks formulated for use on the non food contact surfaces of food packaging and articles intended to come into contact with food October 2005

More information

EudraLex. The Rules Governing Medicinal Products in the European Union Volume 4

EudraLex. The Rules Governing Medicinal Products in the European Union Volume 4 Ref. Ares(2015)283695-23/01/2015 PT CHAPTER 5 PRODUCTION EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products quality, safety and efficacy EudraLex

More information

Implementing New USP Chapters for Analytical Method Validation

Implementing New USP Chapters for Analytical Method Validation Implementing New USP Chapters for Analytical Method Validation March 2010 Ludwig Huber Fax.: +49 7243 602 501 E-mail: [email protected] Today s Agenda Handling Method Changes vs. Adjustments

More information

UNIVERSITY OF PARMA INTERDEPARTMENTAL CENTRE FOR INNOVATION IN HEALTH PRODUCTS, BIOPHARMANET-TEC

UNIVERSITY OF PARMA INTERDEPARTMENTAL CENTRE FOR INNOVATION IN HEALTH PRODUCTS, BIOPHARMANET-TEC UNIVERSITY OF PARMA INTERDEPARTMENTAL CENTRE FOR INNOVATION IN HEALTH PRODUCTS, BIOPHARMANET-TEC RULES FOR THE USE OF THE CENTER EQUIPMENTS ACQUIRED WITHIN THE AGREEMENT BETWEEN THE UNIVERSITY OF PARMA

More information

Guidelines for the Acceptance of Manufacturer's Quality Assurance Systems for Welding Consumables

Guidelines for the Acceptance of Manufacturer's Quality Assurance Systems for Welding Consumables (1987) Guidelines for the Acceptance of Manufacturer's Quality Assurance Systems for Welding Consumables 1. General 1.1 Introduction 1.1.1 The present guidelines are to serve as a supplement to the IACS

More information

SCHEDULE M GOOD MANUFACTURING PRACTICES AND REQUIREMENTS OF PREMISES, PLANT AND EQUIPMENT FOR PHARMACEUTICAL PRODUCTS

SCHEDULE M GOOD MANUFACTURING PRACTICES AND REQUIREMENTS OF PREMISES, PLANT AND EQUIPMENT FOR PHARMACEUTICAL PRODUCTS SCHEDULE M GOOD MANUFACTURING PRACTICES AND REQUIREMENTS OF PREMISES, PLANT AND EQUIPMENT FOR PHARMACEUTICAL PRODUCTS GAZETTE OF INDIA EXTRAORDINARY, PART II-SECTION 3, SUB-SECTION (i)] MINISTRY OF HEALTH

More information

Astellas Ireland Company Ltd. (Kerry Plant) Ampoule Inspection Machine. Eoin O Sullivan 5th June 2014

Astellas Ireland Company Ltd. (Kerry Plant) Ampoule Inspection Machine. Eoin O Sullivan 5th June 2014 Astellas Ireland Company Ltd. (Kerry Plant) Ampoule Inspection Machine Eoin O Sullivan 5th June 2014 Facility History Location. AICL-Dublin Plant AICL-Kerry Plant AICL-Kerry Plant Establishment September

More information

Solid dosage forms testing: Disintegration test and tablet friability and hardness

Solid dosage forms testing: Disintegration test and tablet friability and hardness Specialized Laboratory for Drug production (N111049) Instructions Solid dosage forms testing: Disintegration test and tablet friability and hardness Tutor: Ing. Jiří Petrů Study program: Drug synthesis

More information

TABLET REFORMULATION CASE STUDY. Executive Summary

TABLET REFORMULATION CASE STUDY. Executive Summary TABLET REFORMULATION Executive Summary A large European pharmaceutical company contracted Aptuit to reformulate a tablet with existing dosage strengths of 25 mg and 50 mg. The client required smaller strengths

More information

COMMISSION DIRECTIVE 2003/94/EC

COMMISSION DIRECTIVE 2003/94/EC L 262/22 COMMISSION DIRECTIVE 2003/94/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal

More information

Version 1.0 November 2013 Developed by: Working group of the HPAI Aseptic Services Special Interest Group (ASSIG)

Version 1.0 November 2013 Developed by: Working group of the HPAI Aseptic Services Special Interest Group (ASSIG) (H-PIC\S) Version 1.0 November 2013 Developed by: Working group of the HPAI Aseptic Services Special Interest Group (ASSIG) The working group of the HPAI ASSIG was chaired by: Aisling Collins BSc (Pharm),

More information

Standard Operating Procedure Title: Manufacturing Rework Procedure

Standard Operating Procedure Title: Manufacturing Rework Procedure DR BPN RBPN WIP Deviation Report Batch Production Number Reworked Batch Production Number Work in Progress Area PS1 Production Staging Area 1 PS2 Production Staging Area 2 IP Interim Production Staging

More information

Working Party on Control of Medicines and Inspections. Final Version of Annex 16 to the EU Guide to Good Manufacturing Practice

Working Party on Control of Medicines and Inspections. Final Version of Annex 16 to the EU Guide to Good Manufacturing Practice Version 8 (final) EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals and cosmetics Brussels, July 2001 S\common\legal-legislation\75-319nd81-851\91-356\eudralexvol4\Annex

More information

Design, Operation and Management of GTP/GMP Cell Engineering Facilities

Design, Operation and Management of GTP/GMP Cell Engineering Facilities Design, Operation and Management of GTP/GMP Cell Engineering Facilities Scott R. Burger, MD Advanced Cell & Gene Therapy BFDA 2007 International Symposium on Regulation of Human Cell and Tissue- Based

More information

ANDA CHECKLIST FOR CTD or ectd FORMAT FOR COMPLETENESS and ACCEPTABILITY of an APPLICATION FOR FILING

ANDA CHECKLIST FOR CTD or ectd FORMAT FOR COMPLETENESS and ACCEPTABILITY of an APPLICATION FOR FILING ANDA CHECKLIST FOR CTD or ectd FORMAT FOR COMPLETENESS and ACCEPTABILITY of an APPLICATION FOR FILING For More Information on Submission of an ANDA in Electronic Common Technical Document (ectd) Format

More information

PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013)

PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013) January 2013 RESTRICTED PROPOSED UPDATED TEXT FOR WHO GOOD MANUFACTURING PRACTICES FOR PHARMACEUTICAL PRODUCTS: MAIN PRINCIPLES (JANUARY 2013) DRAFT FOR COMMENTS Please address any comments on this proposal

More information

Customized Nutritional Solutions For Laboratory Animals

Customized Nutritional Solutions For Laboratory Animals A LT R O M I N Customized Nutritional Solutions For Laboratory Animals Dear Sir or Madam, we would like to thank you for a good and successful co-operation in 2008 and furthermore we wish you and your

More information

Journal of Chemical and Pharmaceutical Research

Journal of Chemical and Pharmaceutical Research Available on line www.jocpr.com Journal of Chemical and Pharmaceutical Research ISSN No: 0975-7384 CODEN(USA): JCPRC5 J. Chem. Pharm. Res., 2011, 3(2):892-898 World Health Organization s Guidelines for

More information

Deviation and Out of Specification Handling

Deviation and Out of Specification Handling Deviation and Out of Specification Handling APV Training Course GMP Requirements June,10th to11th 2004 Istanbul, Turkey Dr. Jürgen Mählitz GMP Inspector Fronhof 10 D-86152 Augsburg Germany Dr. Jürgen Mählitz

More information

Compilation of key GMP requirements in us and Japan for Tablet Manufacturing

Compilation of key GMP requirements in us and Japan for Tablet Manufacturing International Journal of Drug Development & Research October-December 2011 Vol. 3 Issue 4 ISSN 0975-9344 Available online http://www.ijddr.in Covered in Official Product of Elsevier, The Netherlands 2010

More information

Annex 2 Good trade and distribution practices for pharmaceutical starting materials

Annex 2 Good trade and distribution practices for pharmaceutical starting materials World Health Organization WHO Technical Report Series, No. 917, 2003 Annex 2 ood trade and distribution practices for pharmaceutical starting materials Introductory note 36 Scope 37 eneral considerations

More information

STABILITY TESTING OF ACTIVE SUBSTANCES AND PHARMACEUTICAL PRODUCTS

STABILITY TESTING OF ACTIVE SUBSTANCES AND PHARMACEUTICAL PRODUCTS RESTRICTED STABILITY TESTING OF ACTIVE SUBSTANCES AND PHARMACEUTICAL PRODUCTS Discussions are currently ongoing with the WHO Eastern Mediterranean Region towards a synergistic approach in developing a

More information

Annex 4 Good Manufacturing Practices for pharmaceutical products: main principles

Annex 4 Good Manufacturing Practices for pharmaceutical products: main principles World Health Organization WHO Technical Report Series, No. 908, 2003 Annex 4 Good Manufacturing Practices for pharmaceutical products: main principles Introduction 37 General considerations 39 Glossary

More information

Community Guide to Good Practice For Feed Additive and Premixture Operators

Community Guide to Good Practice For Feed Additive and Premixture Operators Community Guide to Good Practice For Feed Additive and Premixture Operators INTRODUCTION This European Guide of Practice for Animal Feed Additive and Premixture Operators ( Guide ) responds to the Regulation

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) European Medicines Agency Inspections London, 17 December 2003 CPMP/QWP/122/02, rev 1 corr COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) GUIDELINE ON STABILITY TESTING: STABILITY TESTING OF EXISTING

More information

Guideline on Process Validation

Guideline on Process Validation 1 2 3 4 29 March 2012 EMA/CHMP/CVMP/QWP/70278/2012-Rev1 Committee for Medicinal Products for Human Use (CHMP) Committee for Medicinal Products for Veterinary Use (CVMP) 5 6 Draft Draft Agreed by CHMP /

More information

cgmp Challenges for Cord Blood Banks

cgmp Challenges for Cord Blood Banks cgmp Challenges for Cord Blood Banks Donna M. Regan, MT(ASCP)SBB St. Louis Cord Blood Bank @ SSM Cardinal Glennon Children s s Medical Center Cord Blood Bank processing facility challenges What does cgmp

More information

BEST PRACTICE FOR MAXIMUM TABLET QUALITY, AVOIDING THE FDA WARNING LETTER 483.

BEST PRACTICE FOR MAXIMUM TABLET QUALITY, AVOIDING THE FDA WARNING LETTER 483. White Paper ORAL SOLID DOSAGE: THE TABLET BEST PRACTICE FOR MAXIMUM TABLET QUALITY, AVOIDING THE FDA WARNING LETTER 483. During the period 2008 through 2011, the FDA drew up 42 warning letters recalling

More information

Steinbeis-Transferinstitut Life Sciences Technologies der Steinbeis University Berlin. Certificate

Steinbeis-Transferinstitut Life Sciences Technologies der Steinbeis University Berlin. Certificate Certificate We hereby certify, that the below mentioned production lines meet all GMP-guidelines, EG GMP-Annex 15 guideline and PIC/S guideline PI 006-1 requirements. Product lines: Manufacturer: Series

More information

SPECIFICATION FOR CONSTRUCTION OF UNBOUND GRANULAR PAVEMENT LAYERS

SPECIFICATION FOR CONSTRUCTION OF UNBOUND GRANULAR PAVEMENT LAYERS TNZ B/02:2005 SPECIFICATION FOR CONSTRUCTION OF UNBOUND 1. SCOPE This specification shall apply to the construction of unbound granular pavement layers. The term pavement layer shall apply to any layer

More information

Annex 4 Supplementary guidelines on good manufacturing practices: validation

Annex 4 Supplementary guidelines on good manufacturing practices: validation World Health Organization WHO Technical Report Series, No. 937, 2006 Annex 4 Supplementary guidelines on good manufacturing practices: validation 1. Introduction 2. Scope 3. Glossary 4. Relationship between

More information

Guide to Master Formulae WHO/FWC/IVB/QSS/VQR

Guide to Master Formulae WHO/FWC/IVB/QSS/VQR WHO/FWC/IVB/QSS/VQR 2011 This guidance document GUIDE TO MASTER FORMULAE is one of a series developed by WHO/FWC/IVB Quality, Safety & Standards team upon request from the manufacturers members of the

More information

ISSN 2347-9531 (Print)

ISSN 2347-9531 (Print) Scholars Academic Journal of Pharmacy (SAJP) Sch. Acad. J. Pharm., 2014; 3(2): 178-190 Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources) www.saspublisher.com

More information

COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS

COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS Primer CONTENTS INTRODUCTION...3 QUALITY AND COMPLIANCE IN QUALITY CONTROL LABORATORIES...5 Compliance

More information

ASEAN GUIDELINE ON SUBMISSION OF MANUFACTURING PROCESS VALIDATION DATA FOR DRUG REGISTRATION

ASEAN GUIDELINE ON SUBMISSION OF MANUFACTURING PROCESS VALIDATION DATA FOR DRUG REGISTRATION ASEAN GUIDELINE ON SUBMISSION OF MANUFACTURING PROCESS VALIDATION DATA FOR DRUG REGISTRATION TABLE OF CONTENTS 1. INTRODUCTION... 2 2. SCOPE... 2 3. DATA SUBMISSION REQUIREMENTS... 2 4. CONTENT OF DEVELOPMENT

More information

Example of a food company quality

Example of a food company quality Appendix A manual Example of a food company quality Contents Date: 13/03/95 RME-QLMN-OO Page 1 of 3 Section Title ISO 9001 reference 01 In trod uction 02 Purpose 03 Scope 04 Definitions 05 Management responsibility

More information

Quality Management System for Active pharmaceutical Ingredients manufacturers. Integrating GMP into ISO 9001

Quality Management System for Active pharmaceutical Ingredients manufacturers. Integrating GMP into ISO 9001 Quality Management System for Active pharmaceutical Ingredients manufacturers Integrating GMP into ISO 900 December 997 Table of contents A. Acknowledgement... 3 B. Introduction... 5 C. Glossary... 8 D.

More information

ANALYTICAL METHODS INTERNATIONAL QUALITY SYSTEMS

ANALYTICAL METHODS INTERNATIONAL QUALITY SYSTEMS VALIDATION OF ANALYTICAL METHODS 1 GERT BEUVING INTERNATIONAL PHARMACEUTICAL OPERATIONS TASKS: - Internal auditing - Auditing of suppliers and contract manufacturers - Preparing for and guiding of external

More information

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP)

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS (CVMP) European Medicines Agency Veterinary Medicines and Inspections London, 15 April 2005 EMEA/CVMP/134/02 Rev 1 CPMP/QWP/227/02 Rev 1 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) COMMITTEE FOR VETERINARY

More information

Good Manufacturing Practices (GMP) for Pharmaceutical Excipients

Good Manufacturing Practices (GMP) for Pharmaceutical Excipients Not for publication. This draft text is for circulation for approval by the Joint Committee and has not been published or otherwise officially promulgated. All rights reserved. This document may be reproduced

More information

Making SOP Training More Effective

Making SOP Training More Effective By David Peterson, Director, GMP and Quality Systems, UL EduNeering SOPs are critical to efficient operations, quality control and regulatory compliance. This paper reviews best practices for the Life

More information

Diane Kadidlo MT(ASCP) SBB University of Minnesota Joanna Stanson, M.S. University of Pittsburgh

Diane Kadidlo MT(ASCP) SBB University of Minnesota Joanna Stanson, M.S. University of Pittsburgh Production Records & Documentation Diane Kadidlo MT(ASCP) SBB University of Minnesota Joanna Stanson, M.S. University of Pittsburgh Production Records This Session: Production Records Basic Elements Regulatory

More information

Guidance for Industry Quality Systems Approach to Pharmaceutical CGMP Regulations

Guidance for Industry Quality Systems Approach to Pharmaceutical CGMP Regulations Guidance for Industry Quality Systems Approach to Pharmaceutical CGMP Regulations U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)

More information

Certification Procedure of RSPO Supply Chain Audit

Certification Procedure of RSPO Supply Chain Audit : 1 of 19 Table of Contents 1. Purpose 2. Scope 3. Unit of Certification 3.1 Identity Preserved, Segregation, Mass Balance, 3.2. Book and Claim 4. Definitions 5. Responsibilities 5.1 Head of the Certification

More information

Pharmaceutical Quality Systems: US Perspective

Pharmaceutical Quality Systems: US Perspective Pharmaceutical Quality Systems: US Perspective Rick Friedman Associate Director, Office of Manufacturing and Product Quality Center for Drug Evaluation and Research Topics Background: The ICH Q10 Pharmaceutical

More information

Annex 7 WHO guidelines on transfer of technology in pharmaceutical manufacturing

Annex 7 WHO guidelines on transfer of technology in pharmaceutical manufacturing World Health Organization WHO Technical Report Series, No. 961, 2011 Annex 7 WHO guidelines on transfer of technology in pharmaceutical manufacturing 1. Introduction 2. Scope 3. Glossary 4. Organization

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE

More information

Sandoz Private Limited 10/22/15

Sandoz Private Limited 10/22/15 Sandoz Private Limited 10/22/15 Department of Health and Human Services Public Health Service Food and Drug Administration Silver Spring, MD 20993 Warning Letter VIA UPS WL: 320-16-01 October 22, 2015

More information

Multivariate Tools for Modern Pharmaceutical Control FDA Perspective

Multivariate Tools for Modern Pharmaceutical Control FDA Perspective Multivariate Tools for Modern Pharmaceutical Control FDA Perspective IFPAC Annual Meeting 22 January 2013 Christine M. V. Moore, Ph.D. Acting Director ONDQA/CDER/FDA Outline Introduction to Multivariate

More information

Annex 7 Guidelines on pre-approval inspections

Annex 7 Guidelines on pre-approval inspections World Health Organization WHO Technical Report Series, No. 902, 2002 Annex 7 Guidelines on pre-approval inspections 1. General 94 2. Glossary 94 3. Objectives 95 4. Priorities 96 5. Preparation for the

More information

Quality Management System (QMS) for Active Pharmaceutical Ingredients (API) Manufacturers

Quality Management System (QMS) for Active Pharmaceutical Ingredients (API) Manufacturers Quality Management System (QMS) for Active Pharmaceutical Ingredients (API) Manufacturers integrating GMP (ICH Q7a) into ISO (9001: 2000) September 2005 Quality Management System - integrating GMP (ICH

More information

ICH Topic Q 6 A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances.

ICH Topic Q 6 A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. European Medicines Agency May 2000 CPMP/ICH/367/96 ICH Topic Q 6 A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances Step 5 NOTE

More information

Audit Report in the framework of the APIC Audit Programme

Audit Report in the framework of the APIC Audit Programme Audit Report in the framework of the APIC Audit Programme Company Location Address Country Subject of Audit Audit Date Auditor (lead) Co-Auditor(s) Participants Signature of Auditor(s) Lead Auditor Co-Auditor

More information

SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES (GMP): VALIDATION

SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES (GMP): VALIDATION WORLD HEALTH ORGANIZATION ORGANISATION MONDIALE DE LA SANTE Working document QAS/03.055/Rev.2 RESTRICTED SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES (GMP): VALIDATION This document has followed

More information

Directly compressed mini-tablets coated in a solid-wall pan for sustained drug release

Directly compressed mini-tablets coated in a solid-wall pan for sustained drug release Directly compressed mini-tablets coated in a solid-wall pan for sustained drug release March 2012 N. Passerini, B. Albertini, L.Rodriguez Department of Pharmaceutical Sciences, University of Bologna C.

More information

Combination Products. Presented by: Karen S. Ginsbury For: IFF March 2014. PCI Pharma

Combination Products. Presented by: Karen S. Ginsbury For: IFF March 2014. PCI Pharma Combination Products Presented by: Karen S. Ginsbury For: IFF March 2014 Types of products Biological and medical device (freeze dried + syringe dual volume) Medical device and plasma devised product (syringe)

More information

Manufacturing Services. Operational solutions for chemical, pharmaceutical, nutraceutical and cosmetic companies

Manufacturing Services. Operational solutions for chemical, pharmaceutical, nutraceutical and cosmetic companies Manufacturing Services Operational solutions for chemical, pharmaceutical, nutraceutical and cosmetic companies Bringing ideas to life We built our Swiss pharmaceutical company on one idea born over 70

More information

21 Code of Federal Regulations Parts 210 and 211

21 Code of Federal Regulations Parts 210 and 211 21 Code of Federal Regulations Parts 210 and 211 Part 210 - CURRENT GOOD MANUFACTURING PRACTICE IN MANUFACTURING, PROCESSING, PACKING, OR HOLDING OF DRUGS; GENERAL Part 211 - CURRENT GOOD MANUFACTURING

More information

Certificate. We hereby certify, that the below mentioned production lines meet

Certificate. We hereby certify, that the below mentioned production lines meet Certificate We hereby certify, that the below mentioned production lines meet all GMP-guidelines, EG GMP-Annex 15 guideline and PIC/S guideline PI 006-1 requirements. Product lines: PBA 430/430x Manufacturer:

More information

UNICEF s Quality Assurance System for procurement of medicines

UNICEF s Quality Assurance System for procurement of medicines UNICEF s Quality Assurance System for procurement of medicines QA Specialist Peter Svarrer Jakobsen Joint UNICEF, UNFPA and WHO Meeting with Manufacturers and Suppliers UN City, Copenhagen 23 September

More information

HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) GUIDANCE ON MODULE 3 OF THE HOMEOPATHIC MEDICINAL PRODUCTS DOSSIER

HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) GUIDANCE ON MODULE 3 OF THE HOMEOPATHIC MEDICINAL PRODUCTS DOSSIER HOMEOPATHIC MEDICINAL PRODUCT WORKING GROUP (HMPWG) GUIDANCE ON MODULE 3 OF THE HOMEOPATHIC MEDICINAL PRODUCTS DOSSIER DISCUSSION IN THE HMPWG 2003-2005 RELEASE FOR CONSULTATION December 2005 DEADLINE

More information

BQ-9000 Quality Management System. Certified Marketer Requirements

BQ-9000 Quality Management System. Certified Marketer Requirements BQ-9000 Quality Management System Certified Marketer Requirements Revision 3 Effective Date: February 1, 2007 This requirements document has been prepared by the National Biodiesel Accreditation Commission,

More information

Overview of Pre-Approval Inspections

Overview of Pre-Approval Inspections Overview of Pre-Approval Inspections Presented by: Kelli F. Dobilas NWJ-DO Pre-Approval Manager Pre-Approval Drug Inspections What are Pre-Approval Inspections? One of the last reviews of the drug approval

More information

FAO SPECIFICATIONS FOR PLANT PROTECTION PRODUCTS FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS

FAO SPECIFICATIONS FOR PLANT PROTECTION PRODUCTS FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS FAO SPECIFICATIONS FOR PLANT PROTECTION PRODUCTS AGP:CP/313 METAMITRON FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS Rome, 1994 Group on Pesticide Specifications FAO Panel of Experts on Pesticide

More information

Annex 1 WHO good practices for pharmaceutical quality control laboratories

Annex 1 WHO good practices for pharmaceutical quality control laboratories World Health Organization WHO Technical Report Series, No. 957, 2010 Annex 1 WHO good practices for pharmaceutical quality control laboratories General considerations Glossary Part one. Management and

More information

GENERAL REQUIREMENTS FOR THE PROGRAMME OF REFERENCE MATERIAL CERTIFICATION IN SERIAL PRODUCTION

GENERAL REQUIREMENTS FOR THE PROGRAMME OF REFERENCE MATERIAL CERTIFICATION IN SERIAL PRODUCTION International Document OIML 1 st CD GENERAL REQUIREMENTS FOR THE PROGRAMME OF REFERENCE MATERIAL CERTIFICATION IN SERIAL PRODUCTION International Organization of Legal Metrology Contents 01 Scope 2 12

More information